BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34049769)

  • 1. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
    Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
    J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
    Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
    Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
    Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
    Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Melanoma Using Circulating Free DNA.
    Diefenbach RJ; Lee JH; Rizos H
    Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
    Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
    Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
    Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
    PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity of circulating tumor cells in peripheral blood: Detection of heterogeneous BRAF mutations in a patient with advanced melanoma by single-cell analysis.
    Kiniwa Y; Nakamura K; Mikoshiba A; Akiyama Y; Morimoto A; Okuyama R
    J Dermatol Sci; 2018 May; 90(2):211-213. PubMed ID: 29426605
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
    Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
    Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
    Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
    Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
    Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
    J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of BRAFV600E Mutation in Melanoma Patients by Digital PCR of Circulating DNA.
    Burjanivova T; Malicherova B; Grendar M; Minarikova E; Dusenka R; Vanova B; Bobrovska M; Pecova T; Homola I; Lasabova Z; Plank L
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):241-245. PubMed ID: 30676087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.